Laurel Wealth Advisors (California)’s Pacific Biosciences PACB Stock Holding History

Laurel Wealth Advisors (California)’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-25,243	Closed	-$230K	–	723
2022 Q1	$230K	Hold	25,243	–	–	0.02%	674
2021 Q4	$516K	Sell	25,243 -60	-0.2%	-$1.45K	0.04%	442
2021 Q3	$646K	Hold	25,303	–	–	0.12%	201
2021 Q2	$885K	Buy	25,303 +176	+0.7%	+$5.12K	0.11%	190
2021 Q1	$837K	Buy	25,127 +127	+0.5%	+$4.45K	0.13%	177
2020 Q4	$649K	Sell	25,000 -200	-0.8%	-$3.4K	0.1%	202
2020 Q3	$249K	Buy	+25,200	New	+$145K	0.04%	336
2019 Q2	–	Sell	-26,000	Closed	-$188K	–	424
2019 Q1	$188K	Buy	+26,000	New	+$188K	0.05%	369

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Laurel Wealth Advisors (California)'s PACB Position: Q2 2022 in Review

Laurel Wealth Advisors (California) sold out of Pacific Biosciences (PACB) in Q2 2022, closing a stake of 25,243 shares — an estimated $230K sold.

Laurel Wealth Advisors (California) first reported a position in PACB in Q1 2019 and held it in 8 quarters. The position peaked at $885K in Q2 2021. 228 funds tracked by Wall St. Rank hold PACB as of Q2 2022.

Laurel Wealth Advisors (California) reported no remaining Pacific Biosciences position as of Q2 2022 after selling out during the quarter.
Laurel Wealth Advisors (California) sold 25,243 Pacific Biosciences shares in Q2 2022, an estimated $230K.
Laurel Wealth Advisors (California) first reported a position in Pacific Biosciences in Q1 2019 and held it in 8 quarters.
Laurel Wealth Advisors (California)'s Pacific Biosciences position peaked at $885K in Q2 2021.
228 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2022.

Based on Laurel Wealth Advisors (California)'s 13F filing for Q2 2022, filed 12 Aug 2022.